JP2009515951A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515951A5 JP2009515951A5 JP2008541109A JP2008541109A JP2009515951A5 JP 2009515951 A5 JP2009515951 A5 JP 2009515951A5 JP 2008541109 A JP2008541109 A JP 2008541109A JP 2008541109 A JP2008541109 A JP 2008541109A JP 2009515951 A5 JP2009515951 A5 JP 2009515951A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heterocyclyl
- nhc
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 108
- 125000003118 aryl group Chemical group 0.000 claims 49
- 125000000623 heterocyclic group Chemical group 0.000 claims 47
- 150000001875 compounds Chemical class 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000005466 alkylenyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 2
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- ANCWMDJBFXQDOH-AATRIKPKSA-N 2-amino-6-[(e)-2-(3-bromophenyl)ethenyl]-3-methylpyrimidin-4-one Chemical compound O=C1N(C)C(N)=NC(\C=C\C=2C=C(Br)C=CC=2)=C1 ANCWMDJBFXQDOH-AATRIKPKSA-N 0.000 claims 1
- OUYYVOMCJMHXFN-MDZDMXLPSA-N 2-amino-6-[(e)-2-[3-(3-methoxyphenyl)phenyl]ethenyl]-3-methylpyrimidin-4-one Chemical compound COC1=CC=CC(C=2C=C(\C=C\C=3N=C(N)N(C)C(=O)C=3)C=CC=2)=C1 OUYYVOMCJMHXFN-MDZDMXLPSA-N 0.000 claims 1
- ANCWMDJBFXQDOH-WAYWQWQTSA-N 2-amino-6-[(z)-2-(3-bromophenyl)ethenyl]-3-methylpyrimidin-4-one Chemical compound O=C1N(C)C(N)=NC(\C=C/C=2C=C(Br)C=CC=2)=C1 ANCWMDJBFXQDOH-WAYWQWQTSA-N 0.000 claims 1
- OUYYVOMCJMHXFN-KTKRTIGZSA-N 2-amino-6-[(z)-2-[3-(3-methoxyphenyl)phenyl]ethenyl]-3-methylpyrimidin-4-one Chemical compound COC1=CC=CC(C=2C=C(\C=C/C=3N=C(N)N(C)C(=O)C=3)C=CC=2)=C1 OUYYVOMCJMHXFN-KTKRTIGZSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- -1 —C (O) H Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73739905P | 2005-11-15 | 2005-11-15 | |
| PCT/SE2006/001282 WO2007058582A1 (en) | 2005-11-15 | 2006-11-13 | Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515951A JP2009515951A (ja) | 2009-04-16 |
| JP2009515951A5 true JP2009515951A5 (https=) | 2010-01-07 |
Family
ID=38048895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541109A Pending JP2009515951A (ja) | 2005-11-15 | 2006-11-13 | 新規な２−アミノピリミジノンまたは２−アミノピリジノン誘導体およびそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080318985A1 (https=) |
| EP (1) | EP1951682A4 (https=) |
| JP (1) | JP2009515951A (https=) |
| CN (1) | CN101360721A (https=) |
| WO (1) | WO2007058582A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| PE20070135A1 (es) | 2005-06-14 | 2007-03-09 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas |
| CA2628074C (en) | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
| JP5383484B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | 環式基で置換されたアミノジヒドロチアジン誘導体 |
| KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| MX2012006491A (es) | 2009-12-11 | 2012-07-03 | Shionogi & Co | Derivados de oxazina. |
| EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4625026A (en) * | 1982-12-30 | 1986-11-25 | Biomeasure, Inc. | 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections |
| AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| US6777420B2 (en) * | 2001-06-15 | 2004-08-17 | Microbiotix, Inc. | Heterocyclic antibacterial compounds |
| US20030114445A1 (en) * | 2001-06-15 | 2003-06-19 | Chengxin Zhi | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections |
| US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| EP1802588A4 (en) * | 2004-10-15 | 2010-02-17 | Astrazeneca Ab | SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF |
| JP2008516945A (ja) * | 2004-10-15 | 2008-05-22 | アストラゼネカ・アクチエボラーグ | 置換されたアミノ化合物およびそれらの使用 |
| AR053902A1 (es) * | 2005-06-14 | 2007-05-23 | Schering Corp | Inhibidores de aspartil proteasa heterociclicos macrociclicos |
| KR20080025079A (ko) * | 2005-06-14 | 2008-03-19 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
| ATE478070T1 (de) * | 2005-10-27 | 2010-09-15 | Schering Corp | Heterozyklische aspartyl-proteasehemmer |
| JP2009513670A (ja) * | 2005-10-31 | 2009-04-02 | シェーリング コーポレイション | アスパルチルプロテアーゼインヒビター |
-
2006
- 2006-11-13 CN CNA2006800511049A patent/CN101360721A/zh active Pending
- 2006-11-13 US US12/093,634 patent/US20080318985A1/en not_active Abandoned
- 2006-11-13 JP JP2008541109A patent/JP2009515951A/ja active Pending
- 2006-11-13 WO PCT/SE2006/001282 patent/WO2007058582A1/en not_active Ceased
- 2006-11-13 EP EP06813005A patent/EP1951682A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516945A5 (https=) | ||
| JP2009515951A5 (https=) | ||
| RU2526201C2 (ru) | Способ лечения артрита | |
| JP2013502431A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2019522007A5 (https=) | ||
| JP2019094345A5 (https=) | ||
| JP2008510691A5 (https=) | ||
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| JP2010515715A5 (https=) | ||
| JP2009520685A5 (https=) | ||
| JP2017510610A5 (https=) | ||
| JP2004516314A5 (https=) | ||
| JP2018502891A5 (https=) | ||
| JP2007505933A5 (https=) | ||
| JP2017527532A5 (https=) | ||
| JP2011529468A5 (https=) | ||
| JP2020518629A5 (https=) | ||
| JP5084736B2 (ja) | 肺高血圧を処置するためのジアリールウレア | |
| KR102904026B1 (ko) | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 | |
| JP2017519760A5 (https=) | ||
| FI3506900T3 (fi) | Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension | |
| JP2009526834A5 (https=) | ||
| JP2009515950A5 (https=) |